Net Income

Junior miner Walker Lane Resources seeks a strategic partner after permitting woes stalled its 2025 plans. Can it unlock its Nevada gold potential?

A routine regulatory filing reveals First Trust's 4.99% stake in NCC Group, fueling speculation around the struggling cybersecurity firm's future.

Maker's Mark's new partnership with the player-owned Unrivaled league is more than a sponsorship; it's a strategic bet on the future of sports.

Klaviyo appoints a veteran scaler as co-CEO in a bold move to let its founder focus solely on AI. Is this the new leadership model for tech dominance?

A former oil driller pivots to advanced recycling, but can its plastics-to-fuel plant navigate financial risks and environmental scrutiny in Texas?

HPP's routine preferred stock payout seems minor, but it reveals a deeper story of financial health and a strategic bet on a tech and media rebound.

With its 2026 Investor Day nearing, PHINIA aims to prove its dual-path strategy is the key to powering a diverse, carbon-conscious industrial future.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

Hapag-Lloyd renews a key $550M funding facility, revealing a critical strategy for financial resilience in the turbulent global shipping industry.

A massive silver discovery in Nevada isn't just a win for one company; it's a strategic move to secure America's tech and energy future. Here's why.

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A home remodeler is a top IT workplace. The defense sector must learn from its model for talent development, which holds strategic national security lessons.

Why a top security leader's move from a tech giant to a specialized firm signals a major shift in the fight for digital resilience. A deep dive.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.